Tıp Fakültesi / Faculty of Medicine

Permanent URI for this collectionhttps://hdl.handle.net/11727/1403

Browse

Filters

2018 - 20206

Settings

Author: search.filters.author.Pehlivanoglu, SeckinHas files: No

Search Results

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    Successful Thrombolysis of A Subacute Prosthetic Valve Thrombosis With Modified Ultra-Slow Thrombolytic Therapy
    (2018) Altay, Hakan; Kocabas, Umut; Yildirimturk, Ozlem; Ozkalayci, Flora; Saritas, Bulent; Pehlivanoglu, Seckin; https://orcid.org/0000-0001-6424-9399; 29943853; AAE-1392-2021; AAG-5856-2020; ABC-9264-2021
    Prosthetic valve thrombosis is a serious complication of heart valve surgery. According to the recent studies, thrombolytic therapy is an important alternative therapy to the open heart surgery with successful outcomes. We present a case of a prosthetic mitral valve thrombosis who was successfully treated with modified ultra-slow thrombolytic therapy.
  • No Thumbnail Available
    Item
    Reply to The Letter to The Editor: Successful Thrombolysis of A Subacute Prosthetic Valve Thrombosis with Modified Ultra-Slow Thrombolytic Therapy
    (2018) Altay, Hakan; Kocabas, Umut; Yildirimturk, Ozlem; Ozkalayci, Flora; Saritas, Bulent; Pehlivanoglu, Seckin; 30079510
  • No Thumbnail Available
    Item
    ADHERENCE TO GUIDELINE-DIRECTED MEDICAL AND DEVICE THERAPY IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    (2020) Kocabas, Umut; Kivrak, Tarik; Oztekin, Gulsum Meral Yilmaz; Tanik, Veysel Ozan; Ozdemir, Ibrahim; Kaya, Ersin; Yuce, Elif Ilkay; Demir, Fulya Avci; Dogdus, Mustafa; Pehlivanoglu, Seckin; ABA-3670-2020
  • No Thumbnail Available
    Item
    Acute Coronary Syndrome Associated with Carfilzomib Treatment
    (2020) Kocabas, Umut; Atalay, Figen; Altay, Hakan; Altun, Armagan; Pehlivanoglu, Seckin; 0000-0003-4384-2913; 0000-0002-8506-7583; 0000-0002-3233-8263; 32647445; AAE-1392-2021; B-5507-2014; ABB-5844-2020
  • No Thumbnail Available
    Item
    Predictors of In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Complicated With Cardiogenic Shock
    (2019) Hayiroglu, Mert Ilker; Keskin, Muhammed; Uzun, Ahmet Ozkan; Yildirim, Duygu Ilke; Kaya, Adnan; Cinier, Goksel; Bozbeyoglu, Emrah; Yildirimturk, Ozlem; Kozan, Omer; Pehlivanoglu, Seckin; 29191504
    Background ST-segment elevation myocardial infarction (STEMI) complicated with cardiogenic shock (CS) remains as an unresolved condition causing high morbidity and mortality despite advances in medical treatment and coronary intervention procedures. In the current study, we evaluated the predictors of in-hospital mortality of STEMI complicated with CS. Methods In this retrospective study, we evaluated the predictive value of baseline characteristics, angiographic, echocardiographic and laboratory parameters on in-hospital mortality of 319 patients with STEMI complicated with CS who were treated with primary percutaneous coronary intervention. Patients were divided into two groups consisting of survivors and non-survivors during their index hospitalisation period. Results The mortality rate was found to be 61.3% in the study population. At multivariate analysis after adjustment for the parameters detected in univariate analysis, chronic renal failure, Thrombolysis In Myocardial Infarction (TIMI) post percutaneous coronary intervention (PCI) <= 2, plasma glucose and lactate level, blood urea nitrogen level, Tricuspid Annular Plane Systolic Excursion (TAPSE) and ejection fraction were independent predictors of in-hospital mortality. Conclusions Apart from haemodynamic deterioration, angiographic, echocardiographic and laboratory parameters have an impact on in-hospital mortality in patients with STEMI complicated with CS.
  • No Thumbnail Available
    Item
    Gender-related clinical and management differences in patients with chronic heart failure with reduced ejection fraction
    (2020) Kocabas, Umut; Kivrak, Tarik; Yilmaz Oztekin, Gulsum Meral; Tanik, Veysel O.; Ozdemir, Ibrahim; Kaya, Ersin; Yuce, Elif Ilkay; Avci Demir, Fulya; Dogdus, Mustafa; Altinsoy, Meltem; Ustundag, Songul; Ozyurtlu, Ferhat; Karagoz, Ugur; Karakus, Alper; Urgun, Orsan Deniz; Sinan, Umit Yasar; Mutlu, Inan; Sen, Taner; Astarcioglu, Mehmet Ali; Kinik, Mustafa; Ozden Tok, Ozge; Uygur, Begum; Yeni, Mehtap; Alan, Bahadir; Dalgic, Onur; Altay, Hakan; Pehlivanoglu, Seckin; 33063424; AAE-1392-2021
    Aim Gender-related differences have been described in the clinical characteristics and management of patients with chronic heart failure with reduced ejection fraction (HFrEF). However, published data are conflictive in this regard. Methods We investigated differences in clinical and management variables between male and female patients from the ATA study, a prospective, multicentre, observational study that included 1462 outpatients with chronic HFrEF between January and June 2019. Results Study population was predominantly male (70.1%). In comparison to men, women with chronic HFrEF were older (66 +/- 11 years vs 69 +/- 12 years, P < .001), suffered more hospitalisations and presented more frequently with NYHA class III or IV symptoms. Ischaemic heart disease was more frequent in men, whereas anaemia, thyroid disease and depression were more frequent in women. No difference was seen between genders in the use rate of renin-angiotensin system inhibitors, beta-blockers, mineralocorticoid receptor antagonists, or ivabradine, or in the proportion of patients achieving target doses of these drugs. Regarding device therapies, men were more often treated with an implantable cardioverter-defibrillator (ICD) and women received more cardiac resynchronisation therapy. Conclusion In summary, although management seemed to be equivalent between genders, women tended to present with more symptoms, require hospitalisation more frequently and have different comorbidities than men. These results highlight the importance of gender-related differences in HFrEF and call for further research to clarify the causes of these disparities. Gender-specific recommendations should be included in future guidelines in HFrEF.